FOR IMMEDIATE RELEASE Contact:Emily GrandahlMarketing Coordinator, MitoActionemily@mitoaction.org(888) 648-6228www.mitoaction.org FDA Approval of KYGEVVI Marks a Defining Moment for Mitochondrial Disease Community and Families Affected by TK2d Boston, MA — November 3, […]
Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease
Originally Published by Tisento Therapeutics on November 3, 2025. Findings Demonstrate the Importance of Addressing Both Fatigue and Cognitive Symptoms of MELAS CAMBRIDGE, Mass., November 3, 2025 – Tisento Therapeutics […]
Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
“The approval of FORZINITY, the first treatment option for Barth syndrome and the first approved mitochondria-targeted therapeutic, is a pivotal victory for the Barth syndrome community and offers hope for […]
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio colleagues and MitoAction BOSTON, MA — September 12, 2025 — BPGbio, […]
FDA denies approval for dichloroacetate (DCA), a treatment for Pyruvate Dehydrogenase Complex Deficiency (PDCD).
Earlier today, Saol Therapeutics shared the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the company’s application for dichloroacetate (DCA) to treat Pyruvate Dehydrogenase Complex Deficiency […]
- 1
- 2
- 3
- …
- 32
- Next Page »
